What will manufacturers have to do to ensure the continued uptake of biosimilars?
China’s emergence as a significant commercial market is forcing manufacturers to re-evaluate their overall business model.
Investors are lining up for the biosimilars market as patents reach expiration and regulatory pathways are defined.
Data analytic strategies can help companies capitalize on personalized medicine.
Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R'D, clinical research, and market growth.